BioSpace News Archive

YishengBio Co., Ltd. and Summit Healthcare Acquisition Corp. announced that they have entered into a definitive agreement for a business combination of Summit and the Company.

BioMarin Pharmaceutical Inc. announced that the Company resubmitted a Biologics License Application to the U.S. Food and Drug Administration for its investigational AAV gene therapy, valoctocogene roxaparvovec, for adults with severe hemophilia A.

Trefoil Therapeutics announced positive Phase 2 results for TTHX1114 in patients with Fuchs Endothelial Corneal Dystrophy.

Scribe Therapeutics Inc. announced it will participate in two upcoming investor conferences: Scribe co-founder and CEO Benjamin Oakes will participate in a panel titled “Gene Editing: Next-Generation Technologies Worth Watching,” at 9:30 a.m. ET on Oct. 3, 2022, at the Chardan Genetic Medicines Conference in New York, NY.

ViCapsys Life Sciences, Inc., announced the appointment of Mr. Richard Rosenblum, Dr. Colleen Delaney, and Mr. Charles Farrahar to the Company’s Board of Directors, effective September 22, 2022.

GENFIT announced the signing of the Share Purchase Agreement and the completion of its acquisition of Versantis AG under the terms announced in its press release on September 19, 2022.

Artivion, Inc., a leading cardiac and vascular surgery company focused on aortic disease, announced the appointment of Elizabeth A. Hoff to its Board of Directors effective October 1, 2022.

McKesson Corporation announced that it has signed an agreement in principle to extend its partnership with CVS Health to distribute pharmaceuticals to mail order and specialty pharmacies, retail pharmacies and distribution centers through June 2027.

Kezar Life Sciences, Inc. announced that three posters will be presented at the upcoming American College of Rheumatology Convergence 2022, which will take place November 10 – 14, 2022 in Philadelphia, PA.

ENDRA Life Sciences Inc., a pioneer of imaging technologies and Thermo Acoustic Enhanced UltraSound, announces an update to its plan to submit a De Novo request for the TAEUS system to the U.S. Food and Drug Administration.